Communiqués Monte Rosa Therapeutics, Inc.

Actions

GLUE

US61225M1027

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 01/07/2026			Varia. 5j.	Varia. 1 janv.
24,02 ^USD	-0,74 %		+15,20 %	+53,19 %

07/05	Monte Rosa Therapeutics, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
20/04	Monte Rosa Therapeutics présente au congrès annuel de l'AACR 2026 des données précliniques sur le potentiel de son dégradateur de colle moléculaire ciblant la cycline E1 (CCNE1) dans le traitement des tumeurs solides avec amplification de CCNE1	CI

Communiqués

02/06	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
20/05	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	AQ
07/05	Monte Rosa Therapeutics: Q1 Earnings Snapshot	AQ
07/05	Monte Rosa Therapeutics : Corporate Presentation – May 2026	PU
07/05	Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates	AQ
05/05	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
22/04	Monte Rosa Therapeutics : AACR 2026 – Selective targeting of CCNE1 using molecular glue degraders for the treatment of CCNE1 amplified cancers	PU
20/04	Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors	GL
17/03	Monte Rosa Therapeutics: Q4 Earnings Snapshot	AQ
17/03	Monte Rosa Therapeutics : Corporate Presentation – March 2026	PU
17/03	Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates	AQ
16/03	Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer	AQ
26/02	Monte Rosa Therapeutics : Corporate Presentation – February 2026	PU
26/02	Monte Rosa Therapeutics : ASCO Genitourinary Cancers Symposium 2026 – MRT-2359 in Combination with Enzalutamide Suppresses Multiple Oncogenic Pathways to Drive Deep and Durable PSA and RECIST Responses in Heavily Pretreated, Metastatic Castration-Resistant Prostate Cancer Harbori	PU
24/02	Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)	AQ
23/02	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	AQ
22/01	Monte Rosa Therapeutics : Keystone Symposia – MRT-6160, a highly selective and first-in-class VAV1-directed molecular glue degrader, demonstrates activity in multiple immune-mediated disease models	PU
09/01	Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering	AQ
07/01	Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	AQ
07/01	Monte Rosa Therapeutics : Corporate Presentation – January 2026	PU
07/01	Monte Rosa Therapeutics : MRT-8102 Phase 1 Clinical Data Update	PU
07/01	Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects	AQ
06/01	Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results	AQ
16/12	Monte Rosa Therapeutics : Corporate Presentation – December 2025	PU
16/12	Monte Rosa Therapeutics : MRT-2359 Phase 1/2 Clinical Data Update	PU